Sasaki, Akinori
Nakamura, Yoshiaki
Mishima, Saori
Kawazoe, Akihito
Kuboki, Yasutoshi
Bando, Hideaki
Kojima, Takashi
Doi, Toshihiko
Ohtsu, Atsushi
Yoshino, Takayuki
Kuwata, Takeshi
Akimoto, Tetsuo
Shitara, Kohei
Article History
Received: 1 November 2018
Accepted: 25 December 2018
First Online: 9 January 2019
Compliance with ethical standards
:
: All procedures followed in this study were in accordance with the Declaration of Helsinki of 1964 and later versions and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. Informed consent for it was obtained from all patients for their being included in the study.
: This is not applicable for this study.
: AS has nothing to disclose. YN reports personal fees from Chugai. SM has nothing to disclose. AK reports research funding from Ono, Sumitomo Dainippon, and Taiho. YK reports consulting or advisory role for Takeda; personal fees from Bayer, Lilly, and Taiho; and research funding from Astra Zeneca, Daiichi Sankyo, Incyte, Taiho, and Takeda. HB reports research funding from Astra Zeneca and Sysmex. TK reports personal fees from MSD; and research funding from Astellas, Bristol-Myers Squibb, MSD, Oncolys BioPharma, Ono, Shionogi. TD reports consulting or advisory role for Amgen, Chugai, Daiichi Sankyo, Kyowa Hakko Kirin, Lilly, MSD, Sumitomo Dainippon, and Taiho; and research funding from Abbvie, Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Janssen, Kyowa Hakko Kirin, Lilly, Merck Serono, MSD, Novartis, Pfizer, Quintiles, Sumitomo Group, Takeda, and Taiho. AO reports personal fees from Bristol-Myers Squibb, Chugai, Ono, and Taiho. TY consulting or advisory role for Chugai, Lilly, Merck Serono, and Sanofi; and research funding from Chugai, GlaxoSmithKline, MSD, Nippon Boehringer Ingelheim, Sanofi, and Sumitomo Dainippon. TK consulting or advisory role for ThermoFisher Inc; personal fees from Chugai and Roche Diagnostics; and research funding from Daiichi Sankyo. TA has nothing to disclose. KS reports consulting or advisory role for Astellas, Bristol-Myers Squibb, Lilly, Ono, Pfizer, and Takeda; personal fees from AbbVie, Novartis, and Yakult; and research funding from Chugai, Daiichi Sankyo, Lilly, MSD, Ono, Sumitomo Dainippon, and Taiho.